Newly Diagnosed DKRd
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
More Information
- Trial Status
- Active, Not Recruiting
- Trial Phase
- Phase 2
- Enrollment
- 75 patients (estimated)
- Sponsors
- University of Chicago Medicine
- Collaborators
- Janssen Research & Development LLC, Amgen
- Tags
- Monoclonal Antibody, CD38
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 972
- NCT Identifier
- NCT03500445
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.